The N-terminal of Icatibant and bradykinin interact with the same Asp residues in the human B2 receptor

European Journal of Pharmacology

Volumn 491, Issue 2-3, 2004, Pages 121-125

  Bellucci, Francesca ^a   Meini, Stefania ^a   Cucchi, Paola ^a   Catalani, Claudio ^a   Giuliani, Sandro ^a   Zappitelli, Sabrina ^b   Rotondaro, Luigi ^b   Quartara, Laura ^a   Giolitti, Alessandro ^a   Maggi, Carlo Alberto ^a  

^a Menarini Ricerche SpA   (Italy)

^b Menarini Biotech ^*  (Italy)

Author keywords

Antagonism; FR190997; G protein coupled receptor; Inositol phosphate; Mutagenesis; Non peptide

Indexed keywords

3 (6 ACETAMIDO 3 PYRIDYL) N [N [2,4 DICHLORO 3 [(2 METHYL 8 QUINOLINYL)OXYMETHYL]PHENYL] N METHYLAMINOCARBONYLMETHYL]ACRYLAMIDE; 8 [2,6 DICHLORO 3 [N [4 (N METHYLCARBAMOYL)CINNAMAMIDOACETYL] N METHYLAMINO]BENZYLOXY] 2 METHYL 4 (2 PYRIDYLMETHOXY)QUINOLINE; ASPARTIC ACID; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRADYKININ; ICATIBANT; LF 160687; MEMBRANE PROTEIN; MEMBRANE RECEPTOR; MEN 11270; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; HUMAN; MUTATION; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; ASPARTIC ACID; BRADYKININ; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PEPTIDE FRAGMENTS; QUINOLINES; RECEPTOR, BRADYKININ B2;

EID: 2342448439     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.03.031     Document Type: Article

References (28)

1. 2 receptor involved in ligand binding and agonist sensing defined by anti-peptide antibodies. J. Biol. Chem. 271:1996;1748-1755
2. 2 receptor. Mol. Pharmacol. 52:1997;16-20
3. 2 receptor antagonist, FR173657. Br. J. Pharmacol. 120:1997;617-624
4. 2 receptor: evidence from mutational analysis. Br. J. Pharmacol. 140:2003;500-506
5. 1A receptor. Br. J. Pharmacol. 130:2000;1263-1268
6. 2 bradykinin receptors is adjacent to and discriminates between the C-terminal residues of subtype-selective ligands. J. Biol. Chem. 273:1998;12210-12218
7. 1 bradykinin receptor depends on interaction between the peptide N-terminal L-lysine and the fourth extracellular domain of the receptor. Mol. Pharmacol. 57:2000;171-179
8. 281 of AT1 receptor is essential for full agonism. J. Biol. Chem. 270:1995;12846-12850
9. Fromme B.J., Katz A.A., Roeske R.W., Millar R.P., Flanagan C.A. Role of Aspartate 7.32(302) of the human gonadotropin-releasing hormone receptor in stabilizing a high-affinity ligand conformation. Mol. Pharmacol. 60:2001;1280-1287
10. 2 receptor is adjacent to a sulfhydryl and is differentiated from the antagonist binding site by chemical cross-linking. J. Biol. Chem. 270:1995;20591-20598
11. 277 in the receptor. J. Biol. Chem. 271:1996;29746-29751
12. Hess J.F., Borkowski J.A., Young G.S., Strader C.D., Ransom R.W. Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor. Biochem. Biophys. Res. Commun. 184:1992;260-268
13. 1 receptor. J. Biol. Chem. 269:1994;30953-30959
14. Hjorth S.A., Thirstrup K., Schwartz T.W. Radioligand-dependent discrepancy in agonist affinities enhanced by mutations in the k-opioid receptor. Mol. Pharmacol. 50:1996;977-984
15. Hock F.J., Wirth K., Albus U., Linz W., Gerhards H.J., Wiemer G., Henke S.T., Breipohl G., König W., Knolle J., Schölkens B.A. Icatibant a new potent and long acting bradykinin antagonist: in vitro studies. Br. J. Pharmacol. 102:1991;769-773
16. 2 bradykinin receptor reveal a different pattern of contacts for peptidic agonists and peptidic antagonists. J. Biol. Chem. 271:1996;28277-28286
17. Kenakin T. Competitive antagonism. Kenakin T. Pharmacologic analysis of drug-interaction. Third ed. 1997;331-373 Lippincott-Raven, Philadelphia
18. Kyle D.J. Structure-based drug design: progress toward the discovery of the elusive bradykinin receptor antagonists. Curr. Pharm. Des. 1:1995;233-254
19. Larson D.L., Jones R.M., Hjiorth S.A., Schwartz T.W., Portoghese P.S. Binding of norbinaltorphimine (norBNI) congeners to wild-type and mutant mu and kappa opioid receptors: molecular recognition loci for the pharmacophore and address components of kappa antagonists. J. Med. Chem. 43:2000;1573-1576
20. 2 bradykinin receptors are structurally compatible and involved in discriminating between subtype-selective agonists. J. Biol. Chem. 272:1997;311-317
21. 2 bradykinin receptor. J. Biol. Chem. 276:2001;41100-41111
22. 2 kinin receptor. J. Pharmacol. Exp. Ther. 289:1999;1250-1256
23. 2 receptor for nonpeptide antagonist ligands recognition. Can. J. Physiol. Pharm. 80:2002;303-309
24. 2 receptor and molecular modelling to define the pharmacophore of non-peptide bradykinin receptor antagonists. Biochem. Pharmacol. 67:2004;601-609
25. 2 bradykinin receptor that is essential for high-affinity agonist binding. Proc. Natl. Acad. Sci. 91:1994;4417-4421
26. 2 bradykinin receptor decrease affinity for bradykinin. Biochem. Biophys. Res. Commun. 201:1994;523-530
27. 2 receptor antagonist. Immunopharmacology. 43:1999;187-194
28. Quartara L., Ricci R., Meini S., Patacchini R., Giolitti A., Amadesi S., Rizzi C., Rizzi A., Varani K., Borea P.A., Maggi C.A., Regoli D. Ala scan analogues of HOE 140. Synthesis and biological activities. Eur. J. Med. Chem. 35:2000;1001-1010